Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001)

Cancer

Volumn 122, Issue 5, 2016, Pages 740-747

  Ou, Wei ^a   Li, Ning ^a   Wang, Si Yu ^a   Li, Jian ^a   Liu, Qian Wen ^a   Huang, Qun Ai ^b   Wang, Bao Xiao ^c  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

bevacizumab; locally advanced; neoadjuvant chemotherapy; nonsmall cell lung cancer; surgery

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PEMETREXED; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; DIARRHEA; DIVERTICULITIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EPISTAXIS; EVENT FREE SURVIVAL; FATIGUE; FEMALE; HEADACHE; HEMOPTYSIS; HUMAN; HYPERTENSION; INDUCTION CHEMOTHERAPY; INFUSION RELATED REACTION; INSOMNIA; LUNG ADENOCARCINOMA; LUNG RESECTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTEINURIA; REOPERATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; ADENOCARCINOMA; CHEMICALLY INDUCED; CLINICAL TRIAL; LUNG NEOPLASMS; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CARBOPLATIN; FATIGUE; FEMALE; HUMANS; HYPERTENSION; INDUCTION CHEMOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEUTROPENIA; PEMETREXED; PNEUMONECTOMY; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 84958871004     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29800     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Datta D, Lahiri B,. Preoperative evaluation of patients undergoing lung resection surgery. Chest. 2003; 123: 2096-2103.
3. Goldstraw P, Crowley J, Chansky K, et al., The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of Malignant Tumours. J Thorac Oncol. 2007; 2: 706-714.
4. Ramnath N, Dilling TJ, Harris LJ, et al., Treatment of stage III non-small cell lung cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143: e314S-e340S.
5. Auperin A, Le Pechoux C, Rolland E, et al., Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28: 2181-2190.
6. Rengan R, Maity AM, Stevenson JP, Hahn SM,. New strategies in non-small cell lung cancer: improving outcomes in chemoradiotherapy for locally advanced disease. Clin Cancer Res. 2011; 17: 4192-4199.
7. Curran WJ Jr, Paulus R, Langer CJ, et al., Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011; 103: 1452-1460.
8. NSCLC Meta-Analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014; 383: 1561-1571.
9. Albain KS, Swann RS, Rusch VW, et al., Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009; 374: 379-386.
10. Stupp R, Mayer M, Kann R, et al., Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol. 2009; 10: 785-793.
11. Albain KS, Rusch VW, Crowley JJ, et al., Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995; 13: 1880-1892.
12. Sandler A, Gray R, Perry MC, et al., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550.
13. Reck M, von Pawel J, Zatloukal P, et al., Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009; 27: 1227-1234.
14. Herbst RS, O'Neill VJ, Fehrenbacher L, et al., Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol. 2007; 25: 4743-4750.
15. Niho S, Kunitoh H, Nokihara H, et al., Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer. 2012; 76: 362-367.
16. Patel JD, Socinski MA, Garon EB, et al., PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013; 31: 4349-4357.
17. Patel JD, Hensing TA, Rademaker A, et al., Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009; 27: 3284-3289.
18. Casey EM, Harb W, Bradford D, et al., Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaive patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116. J Thorac Oncol. 2010; 5: 1815-1820.
19. Stevenson JP, Langer CJ, Somer RA, et al., Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer. Cancer. 2012; 118: 5580-5587.
20. Chaft JE, Rusch V, Ginsberg MS, et al., Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. J Thorac Oncol. 2013; 8: 1084-1090.
21. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
22. Robinson LA, Wagner H Jr, Ruckdeschel JC,. Treatment of stage IIIA non-small cell lung cancer. Chest. 2003; 123: 202S-220S.
23. Grunenwald DH, Andre F, Le Pechoux C, et al., Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg. 2001; 122: 796-802.
24. Galetta D, Cesario A, Margaritora S, et al., Enduring challenge in the treatment of nonsmall cell lung cancer with clinical stage IIIB: results of a trimodality approach. Ann Thorac Surg. 2003; 76: 1802-1808; discussion 1808-1809.
25. Ichinose Y, Fukuyama Y, Asoh H, et al., Induction chemoradiotherapy and surgical resection for selected stage IIIB non-small-cell lung cancer. Ann Thorac Surg. 2003; 76: 1810-1814; discussion 1815.
26. Stamatis G, Eberhard W, Pottgen C,. Surgery after multimodality treatment for non-small-cell lung cancer. Lung Cancer. 2004; 45 (suppl 2): S107-S112.
27. Thomas M, Rube C, Hoffknecht P, et al., Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008; 9: 636-648.